Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: Current status and recent developments

Current Opinion in Oncology

Volumn 22, Issue 4, 2010, Pages 330-335

  Reynoso, David ^a   Trent, Jonathan C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adjuvant; GIST; imatinib; neoadjuvant

Indexed keywords

IMATINIB; PLACEBO;

ADJUVANT THERAPY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; HUMAN; MEDICAL DECISION MAKING; METABOLISM; MUTATIONAL ANALYSIS; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TUMOR VOLUME;

CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77953960843     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833aaaad     Document Type: Review

References (39)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580. (Pubitemid 28067289)
2. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.
3. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozo-lomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98:2693-2699.
4. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134.
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
6. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 (Suppl 5):S83-S87.
7. BlankeCD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626-632.
8. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625. (Pubitemid 351264357)
9. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
10. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a rando mised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097-1104.
11. DeMatteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. American Society of Clinical Oncology (ASCO) 2008 Gastrointestinal Cancers Symposium; 2008.
12. DeMatteo RP, Antonescu CR, Chadaram V, et al., American College of Surgeons Oncology Group (ACOSOG). Adjuvant imatinib mesylate in pa tients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005; 23 (16 Suppl):9009.
13. Kang B, Lee J, Ryu M, et al. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors [abstract #e21515]. J Clin Oncol 2009; 27 (Suppl).
14. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radio graphic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16:910-919.
15. Eisenberg BL, Harris J, BlankeCD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent oper able gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99:42-47.
16. Efremidou EI, Liratzopoulos N, Papageorgiou MS, et al. Perforated GIST of the small intestine as a rare cause of acute abdomen: surgical treatment and adjuvant therapy. Case report. J Gastrointestin Liver Dis 2006; 15:297-299.
17. Todoroki T, Sano T, Sakurai S, et al. Primary omental gastrointestinal stromal tumor (GIST). World J Surg Oncol 2007; 5:66.
18. Castillo-Sang M, Mancho S, Tsang AW, et al. A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature. World J Surg Oncol 2008; 6:50.
19. Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89:460-464.
20. Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96:1656-1658.
21. Okuda H, Tanaka H, Ueno M, et al. A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively. Gan To Kagaku Ryoho 2005; 32:1941-1944.
22. Ciresa M, D'Angelillo RM, Ramella S, et al. Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. Tumori 2009; 95:236-239.
23. Hou YY, Zhou Y, Lu SH, et al. Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. World J Gastroenterol 2009; 15:1910-1913.
24. Nakajima S, Sonoda K, Kadokawa Y, et al. Successful resection of an advanced gastrointestinal stromal tumor by neoadjuvant chemotherapy with imatinib: a case report. Gan To Kagaku Ryoho 2009; 36:2645-2648.
25. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14:14-24.
26. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245:347-352.
27. Hohenberger P, Oladeji O, Licht T, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST) [abstract #10550]. J Clin Oncol 2009; 27 (15 Suppl).
28. Cassier PA, Blesius AA, Perol D, et al. Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial [abstract #10551]. J Clin Oncol 2009; 27 (15 Suppl).
29. Rink L, Skorobogatko Y, Kossenkov AV, et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 2009; 8:2172-2182.
30. Trent JC, Ramdas L, Dupart J, et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 2006; 107:1898-1908.
31. McAuliffe JC, Lazar AJ, Yang D, et al. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 2007; 13 (22 Pt 1):6727-6734.
32. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST): update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 (Suppl 2):S1-S29; quiz S30.
33. Cassier PA, Dufresne A, Arifi S, et al. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 2008; 9:1211-1222.
34. Raut CP, Bertagnolli MM. Controversies in the surgical management of GIST in the era of imatinib. Oncology (Williston Park) 2009; 23:69; 74-76.
35. Gronchi A, Judson I, Nishida T, et al. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur J Cancer 2009; 45:1103-1106.
36. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465. (Pubitemid 34747864)
37. Miettinen M, LasotaJ. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130:1466-1478.
38. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10:1045-1052.
39. Battochio A, Mohammed S, Winthrop D, et al. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort. Am J Clin Pathol 133: 149-155.